Prognostic significance of primary tumor localization in patients with metastatic colorectal cancer: Is it beneficial to select targeted treatment? Real-life experience from Turkey

Basit Öğe Kaydı
dc.authorid0000-0003-2715-4002
dc.authorid0000-0002-5823-1704
dc.authorid0000-0002-9815-1848
dc.authorid0000-0001-7934-7039
dc.contributor.authorÇakan, Burçin
dc.contributor.authorAçıkgöz, Özgür
dc.contributor.authorBilici, Ahmet
dc.contributor.authorDemir, Tarık
dc.contributor.authorÖven, Bala Başak
dc.contributor.authorHamdard, Jamshid
dc.contributor.authorOlmuşçelik, Oktay
dc.contributor.authorÖlmez, Ömer Fatih
dc.contributor.authorŞeker, Mesut
dc.contributor.authorYıldız, Özcan
dc.date.accessioned2021-11-30T06:55:13Z
dc.date.available2021-11-30T06:55:13Z
dc.date.issued2021
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractPurpose: The purpose of this study was to investigate the prognostic value,and the effect of primary tumor location on targeted therapy selection in patients with metastatic colorectal cancer (mCRC). Methods: A total of 201 patients with de novo mCRC who received first line treatment were retrospectively analyzed. Clinicopathological features, treatment outcomes, the primary tumor surgery, metastasectomies/local therapies and survivals were evaluated in terms of both RAS mutation status and primary tumor sidedness. Results: Tumor localization showed 140 (69.7%) patients with left-sided and 61 (30.3%) with right-sided tumors. Median progression-free survival (PFS) and overall survival (OS) were significantly shorter in patients with right-sided tumor than those with left-sided tumors (10.1 vs 12.9 months, p=0.005; 25 vs 44.4 months, p=0.008, respectively). In addition,the median OS interval of patients receiving anti-VEGF containing regimen was better than those treated with anti-EGFR containing regimen (50.7 vs. 26.9 months, p=0.001). Multivariate analysis indicated that age (HR:0.41,p=0.045), primary tumor resection (HR:0.41,p=0.037) and primary tumor localization (HR:0.38,p=0.021) for PFS and age (HR:0.39, p=0.09), the presence of BRAF mutation (HR:0.59,p=0.019) and the type of targeted therapy (HR:3.16,p=0.025) for OS were independent prognostic factors. Conclusions: Our results showed that primary tumor location is a prognostic factor in mCRC patients regardless of RAS status. Primary tumor location before treatment decision may be a simple indicator predicting survival and in choosing targeted agent.
dc.identifier.citationÇakan, B., Açıkgöz, Ö., Bilici, A., Demir, T., Öven, B. B., Hamdard, J. ... Yıldız, Ö. (2021). Prognostic significance of primary tumor localization in patients with metastatic colorectal cancer: Is it beneficial to select targeted treatment? Real-life experience from Turkey. Journal of B.U.ON., 26(5), 1908-1917.
dc.identifier.endpage1917
dc.identifier.issn1107-0625
dc.identifier.issue5
dc.identifier.scopusqualityQ3
dc.identifier.startpage1908
dc.identifier.urihttps://hdl.handle.net/20.500.12511/8589
dc.identifier.volume26
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherZerbinis Publications
dc.relation.ispartofJournal of B.U.ON.en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsAttribution 4.0 International*
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.subjectAnti-EGFR Therapy
dc.subjectAnti-VEGF Therapy
dc.subjectColorectal Cancer
dc.subjectRAS Mutation
dc.subjectTumor Sidedness
dc.titlePrognostic significance of primary tumor localization in patients with metastatic colorectal cancer: Is it beneficial to select targeted treatment? Real-life experience from Turkey
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Acikgoz-Ozgur-2021.pdf
Boyut:
1002.45 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu